Traws Pharma, Inc. (NASDAQ:TRAW) Sees Large Drop in Short Interest

Traws Pharma, Inc. (NASDAQ:TRAW) was the recipient of a significant decrease in short interest during the month of October. As of October 31st, there was short interest totalling 7,400 shares, a decrease of 23.7% from the October 15th total of 9,700 shares. Based on an average daily volume of 10,200 shares, the short-interest ratio is presently 0.7 days. Currently, 0.3% of the company’s stock are sold short.

Traws Pharma Stock Down 10.6 %

TRAW stock opened at $4.99 on Friday. The company has a market capitalization of $9.13 million, a price-to-earnings ratio of -0.04 and a beta of 1.41. Traws Pharma has a twelve month low of $4.44 and a twelve month high of $27.50.

Traws Pharma (NASDAQ:TRAW) last released its earnings results on Thursday, August 15th. The company reported ($4.87) earnings per share for the quarter. Traws Pharma had a negative net margin of 60,641.14% and a negative return on equity of 144.95%. The firm had revenue of $0.06 million during the quarter. On average, research analysts predict that Traws Pharma will post -146 earnings per share for the current fiscal year.

About Traws Pharma

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.